Dyax Corp. Presents DX-4012 Data at the 2015 American Society of Hematology Annual Meeting

Loading...
Loading...
Dyax Corp.
DYAX
today announced a poster presentation describing preclinical data for DX-4012, the Company's fully human monoclonal antibody to activated Factor XII (Factor XIIa), was presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 5-8, 2015 in Orlando, Florida. "The poster presented at ASH this year describes how DX-4012 demonstrated anti-thrombotic activity in various animal models, without evidence of increased bleeding risk," said Burt Adelman M.D., Chief Medical Officer and Executive Vice President of Research and Development at Dyax. "These data are a significant achievement for the Dyax research team and indicate that DX-4012, either as a monoclonal antibody or as a component of a bispecific antibody, shows potential as a novel antithrombotic therapy." A summary of data presented is below: Title: Discovery and Characterization of a Highly Specific Antibody Inhibitor of Factor XIIa (FXIIa), and the Subsequent Generation of Factor XIIa/Plasma Kallikrein (PK) Bispecific Antibody Date and time: Sunday, December 6, 2015 from 6:00 – 8:00pm ET Abstract #: 83101 Session: 321. Blood Coagulation and Fibrinolytic Factors: Poster II Location: Hall A, Level 2 Summary: In this report, investigators describe the discovery and preclinical evaluation of DX-4012 as a highly selective and potent inhibitor of FXIIa. DX-4012 inhibits the proteolytic activity of FXIIa with an apparent Ki of ~15 pM, and does not inhibit closely related sequence homologs or other coagulation factors at concentrations up to 1 µM. When tested at 1 µM in human plasma, DX-4012 prolonged the activated partial thromboplastin time (aPTT) 3.4-fold, with no effect on the prothrombin time (PT). In a baboon arteriovenous shunt model of thrombosis, a single 10mg/kg intravenous infusion reduced platelet and fibrin deposition up to 192 hours after administration, demonstrating an antithrombotic effect with no increased risk of bleeding.
Loading...
Loading...
Posted In: NewsFDAPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...